v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Dec. 31, 2010
Dec. 31, 2009
Product sales, net $ 439,644 $ 265,810 $ 763,020 $ 578,961 $ 862,369 $ 734,495
Cost of goods sold (333,559) (139,536) (568,756) (316,348) (497,954) (368,524)
Inventory adjustment   (122,744)   (185,938) (256,948) (58,773)
Gross profit 106,085 3,530 194,264 76,675 107,467 307,198
Patent impairment charge         (1,749,664)  
Operating, sales and administrative expenses (669,241) (1,158,440) (3,838,818) (2,478,115) (3,294,930) (2,094,303)
Net loss from operations (563,156) (1,154,910) (3,644,554) (2,401,440) (4,937,127) (1,787,105)
Other income (expense):            
Interest expense (479,708) (393,325) (1,715,050) (1,797,305) (2,195,151) (656,450)
Change in fair value of derivative instruments 2,257,627 69,666 1,439,082 932,624 1,709,029 (13,600)
(Gain) loss on settlement of debt       (478,262) (478,262) 105,684
Loss on extinguishment of debt (2,227,437)   (2,227,437)      
Beneficial conversion features   (580,000)   (580,000) (606,400)  
Amortization of debt premium 284,061   284,061      
Charge resulting from triggered anti-dilution provisions within financial instruments   (416,794) (854,560) (416,794) (482,866)  
Other expenses (56,295) (18,500) (209,194) (46,460) (49,990) (88,380)
Total other income (expense) (221,752) (1,338,953) (3,283,098) (2,386,197) (2,103,640) (652,746)
Net loss (784,908) (2,493,863) (6,927,652) (4,787,637) (7,040,767) (2,439,851)
Deemed dividend on Series B Preferred Stock           (985,000)
Net loss applicable to common shareholders         $ (7,040,767) $ (3,424,851)
Weighted average number of common shares outstanding, basic and diluted 16,060,162 9,551,002 13,991,863 9,624,200 9,852,710 [1] 6,042,462 [1]
Basic and diluted net loss per common share $ (0.05) $ (0.26) $ (0.50) $ (0.50) $ (0.71) [1] $ (0.57) [1]
[1] Adjusted for the 200-to-1 reverse stock split